- Thinly traded nano cap IRIDEX (NASDAQ:IRIX) has lowered its guidance for Q4 2017 to $10.2M - 10.3M from $11.0M - 11.1M due to a voluntary recall of its TruFocus LIO Premier, a head-mounted indirect ophthalmoscope used to view and perform procedures on the eye with one of its lasers.
- The company decided to recall the product after receiving three reports that patients experienced permanent eye damage, including focal cataracts and iris burns, in treatments where the TruFocus LIO Premier was used. It says there are 104 of the devices at customer sites worldwide.
- It plans to release Q4 and 2017 results on Tuesday, March 8, after the close.